
Top 5 articles from the MHE print publication in 2025
Key Takeaways
- The U.S. healthcare system is rapidly adopting AI, though some leaders advise against hasty, widespread implementation.
- The FDA approved 46 new drugs in 2025, with significant approvals expected in the year's second half.
The most-viewed articles from our print publication included our November 2025 cover story on AI and our April 2025 cover story on Medicaid cuts.
Managed Healthcare Executive started as a print publication 36 years ago, and we still publish a printed publication each and every month. Here are the five articles published in our print publication in 2025 that garnered the most pageviews when they were posted on our website.
Healthcare's embrace of AI
At first, it was tentative. But now almost all parts of the U.S. healthcare system are racing to adopt some form of artificial intelligence. Some leaders caution about using it too widely, too fast.
Expected FDA approvals in the second half of 2025
Wayritz (rilzabrutinib) and Myqorzo (aficamten) were on the list of drugs that were expected to be approved by the FDA in the second half of 2025. The drug regulator approved a total of 46 new drugs in 2025, 30 of them in the final six months.
The biosimilars report card
It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has developed are mixed
Will the Trump Administration advantage Medicare Advantage?
The new administration bumped up 2026 rates for Medicare Advantage plans.
an early sign that it may treat the plans favorably.
Medicaid Cuts: How Deep Will They Go?
Republicans are aiming for major reductions in federal spending, and Medicaid seems a likely target. But the politics of Medicaid have become tricky as the program has expanded and covered more people.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.























